4fbe30da36
Pentagon-Agent: Vida <HEADLESS>
4.2 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | priority | tags | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | GLP-1 Trends 2025: Real-World Data, Patient Outcomes and Future Therapies | HealthVerity | https://blog.healthverity.com/glp-1-trends-2025-real-world-data-patient-outcomes-future-therapies | 2025 | health | analysis | unprocessed | medium |
|
Content
Real-world GLP-1 outcomes data from HealthVerity's pharmacy claims and clinical data:
Persistence (staying on drug):
- 63% of patients initiating Wegovy/Zepbound in early 2024 remained on therapy at one year (up from 40% in 2023)
- Only 14% persisted after three years
- 22% of semaglutide users and 16% of tirzepatide users stopped within the first year
Weight loss outcomes (real-world vs. trial):
- Semaglutide: 7.7% weight loss after one year (real-world)
- Tirzepatide: 12.4% weight loss after one year (real-world)
- These represent "roughly half the weight loss seen in randomized trials"
- SURMOUNT-5 trial: tirzepatide 20% vs. semaglutide 14%
Demographics:
- Women use GLP-1s at higher rates than men, particularly ages 50-64
- Ages 30-49: women more than twice as likely as men to use
Safety signals:
- ~50% report nausea; one-third report diarrhea (GI effects are primary discontinuation reason)
- Emerging concerns: psychiatric effects, respiratory risks in asthma patients, nutrient deficiencies
Pipeline:
- Oral GLP-1 formulations in development
- Amylin mimetics and dual agonists (mazdutide)
- Muscle-preserving combination therapies
Agent Notes
Why this matters: The 14% three-year persistence figure is the most damning data point in the entire GLP-1 landscape. Even with a year-one improvement (40% → 63%), the three-year data shows a cliff. Combined with the known metabolic rebound within 28 weeks of stopping (Session 22), this means the population receiving durable metabolic benefit is approximately 14% of those who start — or roughly 1.7% of eligible obese/overweight adults (14% of 23% who start).
What surprised me: The year-one improvement (40% → 63% from 2023 to 2024 cohort) suggests adherence programs and better prescribing practices are working. But the three-year cliff persists. This is consistent with the behavioral program data from Sessions 22-23 (near-term improvement with structural exit).
What I expected but didn't find: Any data on adherence by income or insurance type within this real-world dataset. The gender breakdown is useful but the income/race gap remains documented by other sources (Wasden 2026).
KB connections:
- The 63% year-one / 14% year-three pattern directly supports the "continuous treatment required, continuous treatment being removed" pattern from Sessions 17, 20, 22 (journal)
- Real-world outcomes at roughly half trial efficacy strengthens the "structural barriers reduce population-level impact" claim
- Connects to behavioral program data: Omada's 63% post-discontinuation weight maintenance (Session 23) looks even more significant given the standard 14% persistence context
Extraction hints:
- ENRICH existing adherence claims with real-world cohort data: 63% year-one (2024 cohort), 14% year-three
- The real-world/trial gap (7.7% vs. 14% weight loss for semaglutide) could support a claim about effectiveness under real-world access conditions
- Note the denominator problem: persistence data is among those who START, not among all eligible
Context: HealthVerity is a health data company with access to large pharmacy claims datasets. This is commercial analysis, not peer-reviewed research, but tracks with published studies.
Curator Notes (structured handoff for extractor)
PRIMARY CONNECTION: GLP-1 adherence trajectory claims (Sessions 22, 23) — specifically the year-one improvement vs. year-three cliff WHY ARCHIVED: The 2024 cohort year-one improvement (40%→63%) is new and should update the existing year-one adherence figure. The three-year 14% figure remains the structural constraint. EXTRACTION HINT: This source primarily enriches existing adherence claims rather than generating new ones. The key update is the 2024 cohort year-one figure (63%), which represents improvement but doesn't change the trajectory.